Physician profile
James Sosnowchik
NPI 1588674048
$8,057.84
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,925 · 2020: $1,654 · 2021: $1,776 · 2022: $1,716 · 2023: $958 · 2024: $28.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,975.81 | 2019-2023 | Breztri, Symbicort, Tezspire |
| Glaxosmithkline, LLC. | $1,629.85 | 2019-2023 | Trelegy Ellipta, Shingrix, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $884.92 | 2019-2023 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Grifols USA, LLC | $674.13 | 2019-2023 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $553.87 | 2019-2023 | |
| Genentech USA, INC. | $374.15 | 2019-2021 | |
| Harmony Biosciences LLC | $299.71 | 2020-2023 | Wakix |
| Regeneron Healthcare Solutions, INC. | $233.84 | 2019-2022 | |
| Gilead Sciences, INC. | $176.74 | 2021-2024 | |
| Mylan Specialty L.P. | $157.54 | 2019-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $138.79 | 2019-2022 | |
| Axsome Therapeutics, INC. | $126.58 | 2022-2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $126.18 | 2020-2023 | Glassia |
| Genzyme Corporation | $98.07 | 2019-2021 | |
| Amgen INC. | $72.20 | 2021-2023 | Tezspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $68.06 | 2019-2022 | |
| Circassia INC. | $55.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.94 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $37.53 | 2019-2022 | |
| Baxter Healthcare | $36.83 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $35.87 | 2019-2021 | |
| Shire North American Group INC | $32.61 | 2019 | |
| Pulmonx Corporation | $31.06 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Inogen, INC. | $27.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.13 | 2019 | |
| Vapotherm INC | $21.31 | 2022 | |
| Advanced Respiratory, INC | $17.91 | 2021 | |
| Pfizer INC. | $17.58 | 2022 | |
| Medtronic, INC. | $16.46 | 2021 | |
| Insmed, INC. | $15.67 | 2023 | Arikayce |
| Horizon Therapeutics Plc | $15.46 | 2021 | |
| Inspire Medical Systems, INC. | $14.51 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $14.24 | 2022 | |
| Nabriva Therapeutics, Plc | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sosnowchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.